Clinical Trials in DeSoto, Texas

24 recruiting

Showing 120 of 24 trials

Recruiting
Phase 3

EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

Kidney Disease, Chronic
Boehringer Ingelheim11,000 enrolled399 locationsNCT06531824
Recruiting
Phase 2

A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression

Major Depressive Disorder (MDD)
Draig Therapeutics Ltd300 enrolled24 locationsNCT07300969
Recruiting

A Study to Evaluate Sleep Electroencephalogram (EEG) Features (Brain Activity While Sleeping) in Participants With Major Depressive Disorder (MDD)

Depressive Disorder, Major
Janssen Research & Development, LLC80 enrolled14 locationsNCT07258485
Recruiting
Phase 3

A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

Alzheimer Disease
Karuna Therapeutics406 enrolled278 locationsNCT06585787
Recruiting
Phase 2

GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder

Major Depressive Disorder
Syndeio Biosciences, Inc164 enrolled34 locationsNCT06547489
Recruiting
Phase 4

A Study to Evaluate the Effect of KarXT on Urological Safety

Schizophrenia
Bristol-Myers Squibb60 enrolled14 locationsNCT07221877
Recruiting
Phase 3

An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

Schizophrenia
Karuna Therapeutics280 enrolled175 locationsNCT05304767
Recruiting
Phase 2

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia

Schizophrenia
MapLight Therapeutics300 enrolled25 locationsNCT07038876
Recruiting
Phase 3

NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

Schizophrenia
Neurocrine Biosciences284 enrolled21 locationsNCT06963034
Recruiting
Phase 3

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics800 enrolled412 locationsNCT05980949
Recruiting
Phase 3

A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD)
Hoffmann-La Roche1,290 enrolled462 locationsNCT05595642
Recruiting
Phase 3

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

Chronic Obstructive Pulmonary Disease
Sanofi942 enrolled135 locationsNCT07190209
Recruiting
Phase 3

A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)

Generalized Anxiety Disorder
Definium Therapeutics US, Inc.200 enrolled36 locationsNCT06741228
Recruiting
Phase 3

Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder

SchizophreniaBipolar I Disorder
Alkermes, Inc.220 enrolled47 locationsNCT05303064
Recruiting
Phase 3

A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc.522 enrolled60 locationsNCT06894212
Recruiting
Phase 2

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

Asthma
Sanofi1,147 enrolled240 locationsNCT06676319
Recruiting
Phase 3

Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder

Major Depressive Disorder
Neumora Therapeutics, Inc.332 enrolled71 locationsNCT06058039
Recruiting
Phase 2

Aleniglipron Phase 2 in Type 2 Diabetes Mellitus

ObesityWeight LossObese+1 more
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics50 enrolled17 locationsNCT07400588
Recruiting
Phase 2

A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)

Treatment Resistant Depression
atai Therapeutics, Inc.142 enrolled42 locationsNCT06524830
Recruiting
Phase 3

A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

Diabetes Mellitus, Type 1
Novo Nordisk A/S877 enrolled184 locationsNCT07076199